FDA’s advisory committee has endorsed Truqap plus abiraterone and ADT as a treatment option with a favorable benefit-risk ...

- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...

New independent board members with experience in AI infrastructure and the evaluation of entrepreneurial ventures added to form a special committee Special committee to evaluate merits of ...

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas, Dec. 14, ...